The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal

Thrombosis and Haemostasis

Volumn 99, Issue 6, 2008, Pages 1121-

  De Stefano, Valerio ^a   Rossi, Elena ^a   Za, Tommaso ^a   Chiusolo, Patrizia ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

GENE MUTATION; HUMAN; LETTER; MUTATION RATE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; OCCLUSIVE CEREBROVASCULAR DISEASE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTHEMIA; VEIN THROMBOSIS;

CHRONIC DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACRANIAL THROMBOSIS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 44949115919     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0205     Document Type: Letter

References (7)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
2. Kiladjian J-J, Cervantes F, Leebeek FWG, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008; epub ahead of print.
3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-1798.
4. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expetancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-543.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
6. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
7. Bellucci S, Cassinat B, Bonnin N, et al. The V617F JAK2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008, 99: 1119-1120.